Dec 12 |
Mustang Bio files to sell 2.74M shares of common stock for holders
|
Dec 11 |
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
|
Nov 14 |
Mustang Bio GAAP EPS of -$1.23 beats by $0.04
|
Nov 14 |
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
|
Nov 2 |
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
|
Oct 30 |
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|